{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:54:46Z","timestamp":1770224086023,"version":"3.49.0"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomaterials"],"abstract":"<jats:p>Osteoporosis (OP) is a common chronic disease that significantly increases the risk of bone fractures. Pharmacotherapy uses, among others, 17beta-estradiol (E2), which has been replaced in recent years by raloxifene hydrochloride (RLX). The need for long-term, high-dose therapy with these drugs is associated with serious adverse effects. The aim of this review is to analyze the current state of knowledge over the last 5 years (2020\u20132025) regarding the use of nanoparticles (NPs) in the delivery of E2 and RLX, with particular emphasis on their impact on bioavailability, pharmacokinetic profile, reduction in adverse effects, and improvement in the effectiveness of postmenopausal osteoporosis therapy. Preclinical studies show that combining E2 or RLX with various types of NPs reduces cytotoxicity, improves pharmacokinetic parameters, and enhances the therapeutic effects of drugs used in postmenopausal osteoporosis. These effects are mainly attributed to improved pharmacokinetics and controlled drug release, rather than confirmed active tissue targeting. However, these findings are based on preclinical models and require further validation in clinical studies. The analysis concludes that while NP systems significantly enhance the pharmacokinetic profile and safety of E2 and RLX in preclinical models, claims of true bone-specific targeting remain largely unsubstantiated, highlighting a key area for future research.<\/jats:p>","DOI":"10.3390\/nano16030180","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:56:12Z","timestamp":1769615772000},"page":"180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Nanoparticle-Based Delivery of Estrogens and Raloxifen in Postmenopausal Osteoporosis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-4892","authenticated-orcid":false,"given":"Agnieszka","family":"W\u0142odarczyk","sequence":"first","affiliation":[{"name":"Department of Medical Biophysics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Silesia, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0468","authenticated-orcid":false,"given":"Patrycja","family":"Dolibog","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Silesia, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13697137.2021.1951697","article-title":"Medical Treatment of Osteoporosis","volume":"25","author":"Palacios","year":"2022","journal-title":"Climacteric"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal Osteoporosis","volume":"389","author":"Walker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"12","article-title":"Effect of Magnetic Nanoparticles on Hormone Level Changes During Perimenopausal Period and Regulation of Bone Metabolism","volume":"68","author":"Wei","year":"2023","journal-title":"Cell. Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/med.22081","article-title":"Estrogen Deficiency-Mediated Osteoimmunity in Postmenopausal Osteoporosis","volume":"45","author":"Yao","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Thurner, G.C., Haybaeck, J., and Debbage, P. (2021). Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168932"},{"key":"ref_6","first-page":"e29367","article-title":"Postmenopausal osteoporosis: A literature review","volume":"14","author":"Bhatnagar","year":"2022","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, K., Cao, F., Xue, Y., Tao, L., and Zhu, Y. (2022). Three classes of antioxidant defense systems and the development of postmenopausal osteoporosis. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.840293"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e081250","DOI":"10.1136\/bmj-2024-081250","article-title":"Advances in the management of osteoporosis","volume":"390","author":"Hoong","year":"2025","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.22203\/eCM.v052a08","article-title":"Novel post-translational modifications in bone remodeling: Potential therapeutic strategies for osteoporosis","volume":"52","author":"Pan","year":"2025","journal-title":"Eur. Cells Mater."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tan, L., Sheng, B., and Deng, S. (2025). The safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly: A pharmacovigilance and RCT meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1514387"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches","volume":"139","author":"Langdahl","year":"2020","journal-title":"Bone"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, L., Dai, Z., Song, H., Zhang, J., and Li, T. (2024). Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004\u20132023). Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1473756"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/ger.12590","article-title":"Oral bisphosphonates: Adverse effects on the oral mucosa not related to the jaw bones. A scoping review","volume":"39","author":"Psimma","year":"2022","journal-title":"Gerodontology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Li, R., Yuan, X., Chen, X., Ou, Y., and Chen, J. (2024). Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS). Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1358592"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: A narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Elahmer, N.R., Wong, S.K., Mohamed, N., Alias, E., Chin, K.Y., and Muhammad, N. (2024). Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081635"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MS9.0000000000001467","article-title":"Osteoporosis therapy using nanoparticles: A review","volume":"86","author":"Zeghoud","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12951-021-00976-4","article-title":"Remote-controllable bone-targeted delivery of estradiol for the treatment of ovariectomy-induced osteoporosis in rats","volume":"19","author":"Guo","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Elghareeb, M.M., Elshopakey, G.E., Elkhooly, T.A., Salama, B., Samy, A., Bazer, F.W., Elmetwally, M.A., Almutairi, M.H., Aleya, L., and Abdel-Daim, M.M. (2022). Estradiol and zinc-doped nano hydroxyapatite as therapeutic agents in the prevention of osteoporosis; oxidative stress status, inflammation, bone turnover, bone mineral density, and histological alterations in ovariectomized rats. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.989487"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.34172\/apb.2023.072","article-title":"17\u03b2-Estradiol-loaded exosomes for targeted drug delivery in osteoporosis: A comparative study of two loading methods","volume":"13","author":"Farashah","year":"2023","journal-title":"Adv. Pharm. Bull."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"117449","DOI":"10.1016\/j.envres.2023.117449","article-title":"Preparation of fluorescent sensor based on Zn metal-organic framework for detection and determination of raloxifene as an anticancer drug","volume":"240","author":"Madvar","year":"2024","journal-title":"Environ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.maturitas.2023.04.121","article-title":"The role of SERMs in menopausal hormonal treatment","volume":"173","author":"Goldstein","year":"2023","journal-title":"Maturitas"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e20107","DOI":"10.1016\/j.heliyon.2023.e20107","article-title":"Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses","volume":"9","author":"Guo","year":"2023","journal-title":"Heliyon"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114379","DOI":"10.1016\/j.colsurfb.2024.114379","article-title":"Effect of co-loaded vitamin D3 on intravenous injectable raloxifene delivery system","volume":"246","author":"Chang","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Murthy, A., Rao Ravi, P., Kathuria, H., and Malekar, S. (2020). Oral bioavailability enhancement of raloxifene with nanostructured lipid carriers. Nanomaterials, 10.","DOI":"10.3390\/nano10061085"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/10717544.2021.1872742","article-title":"Bioadhesive polymer\/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability","volume":"28","author":"Du","year":"2021","journal-title":"Drug Deliv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1080\/10717544.2022.2111479","article-title":"Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability","volume":"29","author":"Yang","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, H., Yan, W., Luo, D., Li, J., and Yan, D. (2024). A real-world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system (FAERS). Expert Opin. Drug Saf., 1\u20139.","DOI":"10.1080\/14740338.2024.2443960"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.colsurfb.2017.03.047","article-title":"Estradiol-loaded PLGA nanoparticles for improving low bone mineral density of cancellous bone caused by osteoporosis: Application of enhanced charged nanoparticles with iontophoresis","volume":"155","author":"Takeuchi","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Eker, F., Duman, H., Akda\u015f\u00e7i, E., Bolat, E., Sar\u0131ta\u015f, S., Karav, S., and Witkowska, A.M. (2024). A comprehensive review of nanoparticles: From classification to application and toxicity. Molecules, 29.","DOI":"10.3390\/molecules29153482"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"W\u0142odarczyk, A., Gorgo\u0144, S., Rado\u0144, A., and Bajdak-Rusinek, K. (2022). Magnetite nanoparticles in magnetic hyperthermia and cancer therapies: Challenges and perspectives. Nanomaterials, 12.","DOI":"10.3390\/nano12111807"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"042001","DOI":"10.1088\/2057-1976\/ac682c","article-title":"Drug-delivery nanoparticles for bone-tissue and dental applications","volume":"8","author":"Higino","year":"2022","journal-title":"Biomed. Phys. Eng. Express"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1186\/s12967-023-04594-6","article-title":"Multifunctional gold nanoparticles for osteoporosis: Synthesis, mechanism and therapeutic applications","volume":"21","author":"Gao","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_34","first-page":"379","article-title":"Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles","volume":"17","author":"Zhao","year":"2022","journal-title":"Bioact. Mater."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kontogianni, G.I., Coelho, C., Gauthier, R., Fiorilli, S., Quadros, P., Vitale-Brovarone, C., and Chatzinikolaidou, M. (2023). Osteogenic potential of nano-hydroxyapatite and strontium-substituted nano-hydroxyapatite. Nanomaterials, 13.","DOI":"10.3390\/nano13121881"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2101107","DOI":"10.1002\/advs.202101107","article-title":"Osteoporosis remission and new bone formation with mesoporous silica nanoparticles","volume":"8","author":"Lozano","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yusuf, A., Almotairy, A.R.Z., Henidi, H., Alshehri, O.Y., and Aldughaim, M.S. (2023). Nanoparticles as drug delivery systems: A review of the implication of nanoparticles\u2019 physicochemical properties on responses in biological systems. Polymers, 15.","DOI":"10.3390\/polym15071596"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7150\/ntno.77395","article-title":"A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery","volume":"7","author":"Kolimi","year":"2023","journal-title":"Nanotheranostics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11864","DOI":"10.1039\/D4NR04508D","article-title":"More than a delivery system: The evolving role of lipid-based nanoparticles","volume":"17","author":"Karmaker","year":"2025","journal-title":"Nanoscale"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2217\/nnm-2024-0023","article-title":"Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: Simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry","volume":"19","author":"Chauhan","year":"2024","journal-title":"Nanomedicine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s13346-023-01480-y","article-title":"Raloxifene encapsulated spanlastic nanogel for the prevention of bone fracture risk via transdermal administration: Pharmacokinetic and efficacy study in animal model","volume":"14","author":"Ansari","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2100109","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. Nanobiomed Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s13346-023-01427-3","article-title":"QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: Extensive in vitro and in vivo evaluation studies","volume":"14","author":"Pant","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e202216097","DOI":"10.1002\/anie.202216097","article-title":"Protein-based nanoparticles: From drug delivery to imaging, nanocatalysis and protein therapy","volume":"62","author":"Kaltbeitzel","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10856-017-5978-4","article-title":"Morphology effect of nano-hydroxyapatite as a drug carrier of methotrexate","volume":"28","author":"Sun","year":"2017","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Szurkowska, K., Kazimierczak, P., and Kolmas, J. (2021). Mg, Si\u2014Co-Substituted Hydroxyapatite\/Alginate Composite Beads Loaded with Raloxifene for Potential Use in Bone Tissue Regeneration. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062933"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"John, J. (2025). Advancements in nano-based drug delivery systems for therapeutics: A comprehensive review. RSC Pharm., advance article.","DOI":"10.1039\/D5PM00179J"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chen, Y., Wu, X., Li, J., Jiang, Y., Xu, K., and Su, J. (2022). Bone-targeted nanoparticle drug delivery system: An emerging strategy for bone-related disease. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.909408"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.2147\/IJN.S478964","article-title":"Advancements and challenges of nanostructured lipid carriers for wound healing applications","volume":"19","author":"Wathoni","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/2211738508666201214103010","article-title":"A review on designing poly (lactic-co-glycolic acid) nanoparticles as drug delivery systems","volume":"9","author":"Naskar","year":"2021","journal-title":"Pharm. Nanotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.17219\/acem\/186846","article-title":"Advantages and limitations of nanostructures for biomedical applications","volume":"34","author":"Roszkowski","year":"2025","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41413-024-00356-2","article-title":"Bone targeted nano-drug and nano-delivery","volume":"12","author":"Wu","year":"2024","journal-title":"Bone Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1208\/s12249-021-02108-5","article-title":"Primaquine loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsion (NE): Effect of lipid matrix and surfactant on drug entrapment, in vitro release, and ex vivo hemolysis","volume":"22","author":"Wu","year":"2021","journal-title":"AAPS Pharmscitech"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yedgar, S., Barshtein, G., and Gural, A. (2022). Hemolytic activity of nanoparticles as a marker of their hemocompatibility. Micromachines, 13.","DOI":"10.3390\/mi13122091"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Yetisgin, A.A., Cetinel, S., Zuvin, M., Kosar, A., and Kutlu, O. (2020). Therapeutic nanoparticles and their targeted delivery applications. Molecules, 25.","DOI":"10.3390\/molecules25092193"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Namiot, E.D., Sokolov, A.V., Chubarev, V.N., Tarasov, V.V., and Schi\u00f6th, H.B. (2023). Nanoparticles in clinical trials: Analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010787"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1039\/D5MD00571J","article-title":"Delivery strategies to improve the pharmacological efficacy of NRF2 modulators: A review","volume":"16","author":"Bayindir","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12951-025-03442-7","article-title":"Nano-formulations in disease therapy: Designs, advances, challenges, and future directions","volume":"23","author":"Shi","year":"2025","journal-title":"J. Nanobiotechnol."}],"container-title":["Nanomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4991\/16\/3\/180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:13:10Z","timestamp":1770181990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4991\/16\/3\/180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["nano16030180"],"URL":"https:\/\/doi.org\/10.3390\/nano16030180","relation":{},"ISSN":["2079-4991"],"issn-type":[{"value":"2079-4991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}